What is claimed is

1. Topical ophthalmic formulation in the form of an aqueous solution comprising a cyclosporin, hyaluronic acid or one of its salts, and polysorbate 80.

2. Formulation according to claim 1, comprising 0.02 to 2 % by weight of cyclosporin, 0.01 to 2 % by weight of hyaluronic acid or one of its salts, and 0.5 to 40 % by weight of polysorbate 80, based on the formulation's total weight.

3. Formulation according to claim 1, wherein the cyclosporin is a cyclosporin A.

4. Formulation according to claim 1, wherein the hyaluronic acid or its salt has a weight-average molecular weight not inferior to 1,300,000 daltons.

5. Formulation according to claim 4, wherein the hyaluronic acid or its salt has a weight-average molecular weight situated in the region from 1,300,000 to 3,000,000 daltons.

6. Formulation according to claim 1, wherein the hyaluronic acid is present as alkali metal or alkaline-earth metal hyaluronate.

7. Formulation according to claim 6, wherein the hyaluronic acid is present as sodium hyaluronate.

8. Formulation according to claim 2, comprising 0.2 % by weight of cyclosporin A, 0.1 % by weight of hyaluronic acid or one of its salts, and 5 % by weight of polysorbate 80, based on the formulation's total weight.

9. Formulation according to claim 1, further comprising additives.

10. Use of a cyclosporin in association with hyaluronic acid or one of its salts and with polysorbate 80 for the preparation of a formulation in the form of an aqueous solution intended for topical ophthalmic use.

11. Use according to claim 10 wherein the formulation comprises 0.02 to 2 % by weight of cyclosporin, 0.01 to 2 % by weight of hyaluronic acid or one of its salts, and 0.5 to 40 % by weight of polysorbate 80, based on the formulation's total weight.

12. Use according to claim 10, wherein the cyclosporin is a cyclosporin A.

13. Use according to claim 10, wherein the hyaluronic acid or its salt has a weight-average molecular weight not inferior to 1,300,000 daltons.

14. Use according to claim 13, wherein the hyaluronic acid or its salt has a weight-average molecular weight situated in the region from 1,300,000 to 3,000,000 daltons.

15. Use according to claim 10, wherein the hyaluronic acid is present as alkali metal or alkaline-earth metal hyaluronate.

16. Use according to claim 15, wherein the hyaluronic acid is present as sodium hyaluronate.

17. Use according to claim 10, wherein the formulation is intended for the treatment of a keratoconjunctivitis sicca (KCS).

18. Use according to claim 10, wherein the formulation is intended for the treatment of Sjögren's syndrome.

19. Use according to claim 10, wherein the formulation is intended for the treatment of dry-eye syndrome.

20. Use according to claim 10, wherein the formulation is intended for the treatment of chronic vernal keratoconjunctivitis.

21. Use according to claim 10, wherein the formulation is intended for use as a post-operative prophylactic in keratoplasty.